Corecam AG’s Bristol-Myers Squibb BMY Stock Holding History

Corecam AG’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Buy	5,311 +1,125	+27%	+$64.6K	0.26%	45
2026 Q1	$254K	Buy	+4,186	New	+$244K	0.22%	46

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Corecam AG's BMY Position: Q2 2026 in Review

Corecam AG increased its Bristol-Myers Squibb (BMY) stake by 27% in Q2 2026, buying an estimated $64.6K and bringing the position to 5,311 shares worth $306K. The position accounts for 0.26% of the portfolio, ranked #45.

Corecam AG first reported a position in BMY in Q1 2026 and has held it in 2 quarters since. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Corecam AG held 5,311 shares of Bristol-Myers Squibb worth $306K as of Q2 2026.
Corecam AG bought 1,125 Bristol-Myers Squibb shares in Q2 2026, an estimated $64.6K.
Bristol-Myers Squibb made up 0.26% of Corecam AG's portfolio in Q2 2026, its #45 holding.
Corecam AG first reported a position in Bristol-Myers Squibb in Q1 2026 and has held it in 2 quarters since.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Corecam AG's 13F filing for Q2 2026, filed 17 Jul 2026.